For decades, management strategies to curb DKD progression have solely involved optimization of glycemic control and the use of blood pressure-lowering medications, particularly angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), which are also effective in reducing albumin excretion [8]. This evidence concerns the gene ALB and diabetic kidney disease.